Financials
Financial year 2025
H & H PHARMACEUTICALS from Nivelles, company number BE0759775660, closed financial year 2025 with a result of € 8.4 million after tax. For that financial year H & H PHARMACEUTICALS recorded revenue of € 1.7 million and equity of € 27.8 million. Compared with financial year 2024, the result moved from € 3.4 million to € 8.4 million. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 20, 2026.
€ 27.8 million
▲ 43% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 8.4 million
▲ 144% vs 2024
Profit after tax over the fiscal year.
€ 5.3 million
▲ 158% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 27.8 million.
Debts at end 2025
€ 18.5 million
▼ 15% vs 2024
€ 3.5 million is repaid this year. At this pace the long-term loan is gone in ≈ 5 years.
€ 17,285
▲ € 17,228 vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 44 days on average.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | - | - | € 1,735,507 | € 1,671,876 | ▼ 4% |
| Gross margin | € -4,509 | € 219,022 | - | - | |
| Profit after taxes | € 2,406,036 | € 13,903,501 | € 3,423,174 | € 8,357,527 | ▲ 144% |
| Equity | € 2,087,549 | € 15,991,050 | € 19,414,224 | € 27,771,751 | ▲ 43% |
| Total debts | € 21,511,403 | € 26,268,378 | € 22,246,613 | € 19,624,564 | ▼ 12% |
| Cash | € 11,203 | € 378,678 | € 2,052,164 | € 5,294,689 | ▲ 158% |
| Land & buildings | - | € 865,653 | € 896,644 | € 896,644 | |
| Retained profit | € 2,077,549 | € 15,981,050 | € 19,404,224 | € 27,761,751 | ▲ 43% |
| Bank debt | € 21,202,699 | € 25,728,085 | € 21,869,514 | € 18,541,431 | ▼ 15% |
| Balance sheet total | € 23,598,952 | € 42,259,427 | € 41,660,836 | € 47,396,315 | ▲ 14% |
Key figures of H & H PHARMACEUTICALS, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to H & H PHARMACEUTICALS?
What happened at H & H PHARMACEUTICALS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 8.4 million (▲ 144% vs 2024). filed late Source: NBB ↗
- New establishment in Nivelles. KBO
- Start of the company according to the CBE. KBO
In short
From € 2.4 million profit in 2022 to € 8.4 million profit in 2025.
Paid € 127,807 in corporate taxes since 2022.
Best year ever: 2023, with € 13.9 million profit.
Pays suppliers within 44 days on average.
Management
Behind H & H PHARMACEUTICALS are Laurent HAVERBEKE and Koen SMESSAERT. It owns 100% of FUSION MEDICARE, 96% of Soneprophar, 95% of EXPHAR.CH and 93.7% of EXPHAR itself.
Directors
According to the 2025 annual accounts
Establishments
Establishment units
Physical locations of this company
Avenue Thomas Edison 105
1402 Nivelles
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0759.775.660
- VAT number
- BE 0759.775.660
- Registered office
- Avenue Thomas Edison 105, 1402 Nivelles
- Names & denominations
- H & H PHARMACEUTICALS
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 14 December 2020
- Peppol
- Active · Active since 1 Jan 2001
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Opslag
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied